Search

Your search keyword '"Cancer"' showing total 44,804 results

Search Constraints

Start Over You searched for: Descriptor "Cancer" Remove constraint Descriptor: "Cancer" Journal cancer research Remove constraint Journal: cancer research
44,804 results on '"Cancer"'

Search Results

1. Abstract LB237: PVRL2 suppresses antitumor immune responses through PVRIG- and TIGIT-independent pathways

2. Abstract 3180: Suppression of the CPEB3 ribozyme modulates the progression of glioblastoma

3. Inhibition of Ephrin B2 Reverse Signaling Suppresses Multiple Myeloma Pathogenesis

4. Abstract C036: Restoration of T effector cells function by targeting senescent cancer-associated fibroblast in tumor microenvironment of stroma-rich cancers

5. Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity

6. To Tip or Not to Tip: A New Combination for Precision Medicine in Head and Neck Cancer.

7. Single-cell characterization of pulmonary nodules implicates suppression of immunosurveillance across early stages of lung adenocarcinoma

8. Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma

9. Syk inhibition reprograms tumor-associated macrophages and overcomes gemcitabine-induced immunosuppression in pancreatic ductal adenocarcinoma

10. The genomic and epigenomic landscape of double-negative metastatic prostate cancer

11. Profiling the somatic mutational landscape of breast tumors from Hispanic/Latina women reveals conserved and unique characteristics

12. Live Biotherapeutic Products as Cancer Treatments.

13. Polyunsaturated fatty acid-bound alpha-fetoprotein promotes immune suppression by altering human dendritic cell metabolism

14. Abstract LB059: DNA damage and somatic mutations in mammalian cells after irradiation with a nail polish dryer

15. Abstract CT021: Assessing clinical and pharmacodynamic (PD) profiles of patients (pts) with chronic lymphocytic leukemia (CLL) on ianalumab (VAY736) + ibrutinib

16. Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer.

17. Abstract 3878: Targeting Hippo-YAP, BRD4 and RAS-MAPK interplay in lung cancer to forestall drug resistance

18. CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer.

19. Single-Cell Analysis in Lung Adenocarcinoma Implicates RNA Editing in Cancer Innate Immunity and Patient Prognosis.

20. N-myc-Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma.

21. Wnt Signaling in the Phenotype and Function of Tumor-Associated Macrophages.

22. Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis

23. A Genomically and Clinically Annotated Patient-Derived Xenograft (PDX) Resource for Preclinical Research in Non-Small Cell Lung Cancer

24. Challenges and Emerging Opportunities for Targeting mTOR in Cancer.

25. Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2

26. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

27. Abstract 3702: UBE4B interacts with the ITCH E3 ubiquitin ligase to induce Ku70 and c-FLIPL K63/K48 branched polyubiquitination and enhanced neuroblastoma HDACi-mediated apoptosis

28. Abstract 6307: The botanical drug PBI-05204, a supercritical CO₂ extract of Nerium oleander, augments the antitumor efficacy of radiotherapy in treatment of human glioblastoma

29. Abstract 827: A journey to deconvolute the multifaceted functions and context-dependency of cancer driver genes

30. Abstract 3054: Pan-cancer characterization of the tumor mycobiome and its clinical effects

31. Mammary tumor-derived transplants as breast cancer models to evaluate tumor-immune interactions and therapeutic responses

32. Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer

33. Activation of Notch and Myc signaling via B cell-restricted depletion of Dnmt3a generates a consistent murine model of chronic lymphocytic leukemia

34. Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion

35. Quantitative in vivo analyses reveal a complex pharmacogenomic landscape in lung adenocarcinoma

36. Association between Airport-Related Ultrafine Particles and Risk of Malignant Brain Cancer: A Multiethnic Cohort Study

37. Abstract 331: Characterization of neoepitope (neoE)-specific T cells from peripheral blood for adoptive neoTCR-T cell therapy for patients with breast cancer (bc) or ovarian cancer (oc)

38. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non–Small Cell Lung Cancer

39. Nuclear Receptor Coactivator NCOA3 Regulates UV Radiation–Induced DNA Damage and Melanoma Susceptibility

40. Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Responsep53 Pathway SNPs and Mutations Interact to Affect Cancer

41. A Large-Scale Association Study Detects Novel Rare Variants, Risk Genes, Functional Elements, and Polygenic Architecture of Prostate Cancer Susceptibility

42. Survivin Expression Is Differentially Regulated by a Selective Cross-talk between RBM38 and miRNAs let-7b or miR-203a

43. Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers

44. A Transcriptional Regulatory Loop of Master Regulator Transcription Factors, PPARG, and Fatty Acid Synthesis Promotes Esophageal Adenocarcinoma

45. A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models

46. A High-Content Screen Identifies Drugs That Restrict Tumor Cell Extravasation across the Endothelial Barrier

47. Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma

48. Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment

49. Oncogenic TRIM37 Links Chemoresistance and Metastatic Fate in Triple-Negative Breast Cancer.

50. ALPPL2 Is a Highly Specific and Targetable Tumor Cell Surface Antigen

Catalog

Books, media, physical & digital resources